Amplyx Pharmaceuticals
12730 High Bluff Drive
Suite 160
San Diego
California
92130
United States
39 articles about Amplyx Pharmaceuticals
-
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
11/13/2023
Basilea Pharmaceutica Ltd announced that it has entered into an asset purchase agreement with Amplyx Pharmaceuticals, Inc., an affiliate of Pfizer Inc., to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate.
-
Pfizer Acquires Amplyx Pharmaceuticals
4/28/2021
Deal expands anti-infectives pipeline with addition of novel antifungal Phase 2 candidate, Fosmanogepix (APX001) Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease
-
Pfizer is expanding its presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and its lead antifungal compound Fosmanogepix.
-
Amplyx Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting
12/3/2020
Preclinical and clinical data on anti-BKV monoclonal antibody MAU868 highlights promise of ongoing clinical development program for transplant patients
-
Amplyx to Present New Clinical and Preclinical Data for its Two Lead Programs at Upcoming Scientific Conferences
10/16/2020
- Oral presentation of positive phase 2 results from a study of fosmanogepix in candidemia to be presented at IDWeek 2020 - First preclinical and clinical data on anti-BKV monoclonal antibody MAU868 to be presented at Kidney Week 2020
-
Amplyx to Participate in Upcoming Antifungal Webinar Presented by Maxim Group LLC
9/14/2020
Amplyx Pharmaceuticals, announced today that Ciara Kennedy, Ph.D, president and chief executive officer, has been invited to present at A Too Quiet Pandemic – Fungal Disease webinar, presented by Maxim Group LLC and M-Vest, on Thursday September 17th, 2020.
-
Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients
8/17/2020
- MAU868 has the potential to be the first therapeutic to prevent and treat BKV-associated diseases in transplant patients
-
Amplyx Pharmaceuticals Announces Participation in Multiple Upcoming Investor Conferences
8/5/2020
Amplyx Pharmaceuticals , a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced its president and chief executive officer, Ciara Kennedy , Ph.D., will present a corporate overview at the following upcoming inve
-
Clinical Catch-Up: July 20-24
7/27/2020
It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look. -
The company posted Phase II data that showed its experimental asset fosmanogepix demonstrated a treatment success rate of 80%.
-
Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix
7/20/2020
Fosmanogepix met primary efficacy endpoint and demonstrated favorable safety profile in first-line treatment of invasive Candida infections
-
Amplyx Pharmaceuticals to Present at the Upcoming Virtual European Biotech Investor Day 2020
6/24/2020
Amplyx Pharmaceuticals , a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that Ciara Kennedy , Ph.D., president and CEO, plans to present an overview of the company and update on their clinical development
-
BioSpace Movers & Shakers, June 12
6/12/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Amplyx Pharmaceuticals Expands Executive Leadership Team
6/8/2020
Amplyx Pharmaceuticals , a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune syste
-
Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix
5/19/2020
Completes Enrollment of Phase 2 Candida Trial Treats First Patients in Phase 2 Trials in Aspergillus and Candida auris Infections
-
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
5/19/2020
Amplyx Pharmaceuticals, a biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that it has closed a $53 million Series C extension, which brings the Series C round to over $90 million.
-
San Diego-based Amplyx Pharmaceuticals closed a Series C extension round worth $53 million, bringing the Series C round total to more than $90 million.
-
Amplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group's Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
4/29/2020
Amplyx Pharmaceuticals , a clinical stage biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that Ciara Kennedy , Ph.D., President and Chief Executive Officer, will participate in a panel discussing fungal pathogens and the emerging
-
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
2/11/2019
Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development has granted orphan drug designation to APX001, the company's lead drug candidate, for treatment of cryptococcosis.
-
Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
11/13/2018
First Patient has Completed Dosing in Global Phase 2 Clinical Trial for the First-Line Treatment of Patients with Candidemia